Alpheus Medical

SAB to provide meaningful guidance as the company begins a first-in-human (FIH) clinical trial of their proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas

Funds to support first-in-human (FIH) clinical trial of the company’s proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas

Alpheus Medical, Inc., a private clinical-stage biotechnology company, announced initiation of a Phase 2b randomized controlled trial in newly diagnosed glioblastoma, with 10 patients enrolled and additional sites coming online.

Funding will support a randomized Phase 2B study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma.

Executive Chairman of the Board

Vice President, Research & Development

Alpheus Medical is developing an investigational therapy that pairs a tumor-accumulating drug with low-intensity ultrasound to achieve localized pharmacologic activation inside solid tumors.

Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.

Alpheus Medical begins enrollment for a new clinical trial assessing its experimental treatment for **butterfly glioblastoma**, an aggressive brain tumor type. The trial evaluates a therapy developed by the private biotech company, which operates at the clinical-stage. Researchers aim to test safety and efficacy in patients with this rare and challenging cancer subtype.

Oct 2026PR NewswireNews article

Alpheus Medical is testing a novel sonodynamic therapy, called the PoMA platform, in a phase 2b trial for glioblastoma. The therapy targets diffuse tumor cells throughout the brain, a challenge current treatments often fail to address. Early patient enrollment for the trial is already underway.

Apr 2026biopharminternational.comNews article

Alpheus Medical begins a Phase 2b randomized controlled trial testing an experimental therapy for patients with newly diagnosed glioblastoma. The clinical-stage biotech company aims to evaluate the investigational treatment’s efficacy and safety in this aggressive brain cancer patient population. The trial marks a progression from earlier-stage research toward potential broader clinical application.

Apr 2026PR NewswireNews article

Alpheus Medical secures **$52 million** in funding to develop a **non-thermal, tumor-selective therapy** for glioblastoma. The treatment uses **low-intensity diffuse ultrasound** to target tumors precisely. The company aims to translate its technology into clinical applications for improved patient outcomes.

May 2025Medical Design & DevelopmentNews article